Evaluation of bioequivalence after oral, intramuscular, and intravenous administration of racemic ketoprofen in pigs

American Journal of Veterinary Research

Volumn 69, Issue 1, 2008, Pages 108-113

  Raekallio, Marja R ^a   Mustonen, Katja M ^b   Heinonen, Mari L ^a   Peltoniemi, Olli A T ^a   Säkkinen, Mia S ^a   Peltoniemi, S Marikki ^a   Honkavaara, Juhana M ^a   Vainio, Outi M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Vetcare Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DOLOVET; KETOPROFEN; ROMEFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SWINE;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; KETOPROFEN; SWINE; THERAPEUTIC EQUIVALENCY;

ANIMALIA; SUIDAE;

EID: 38749135844     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.1.108     Document Type: Article

References (36)

1. Zoric M, Sjolund M, Persson M, et al. Lameness in piglets. Abrasions in nursing piglets and transfer of protection towards infections with streptococci from sow to offspring. J Vet Med B infect Dis Vet Public Health 2004;51:278-284.
2. Zoric M, Stern S, Lundeheim N, et al. Four-year study of lameness in piglets at a research station. Vet Rec 2003;153:323-328.
3. Heinonen M, Oravainen J, Orro T, et al. Lameness and fertility of sows and gilts in randomly selected loose-housed herds in Finland. Vet Rec 2006;159:383-387.
4. Hill BD, Corney BG, Wagner TM. Importance of Staphylococcus hyicus ssp hyicus as a cause of arthritis in pigs up to 12 weeks of age. Aust Vet J 1996;73:179-181.
5. Nielsen EO, Nielsen NC, Friis NF. Mycoplasma hyosynoviae arthritis in grower-finisher pigs. J Vet Med A Physiol Pathol Clin Med 2001;48:475-486.
6. Petersen HH, Dideriksen D, Christiansen BM, et al. Serum haptoglobin concentration as a marker of clinical signs in finishing pigs. Vet Rec 2002;151:85-89.
7. Friton GM, Philipp H, Schneider T, et al. Investigation on the clinical efficacy and safety of meloxicam (Metacam) in the treatment of non-infectious locomotor disorders in pigs. Berl Munch Tierarztl Wochenschr 2003;116:421-426.
8. Lascelles BD, Henderson AJ, Hackett IJ. Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders. J Small Anim Pract 2001;42:587-593.
9. Owens JG, Kamerling SG, Stanton SR, et al. Effects of ketoprofen and phenylbutazone on chronic hoof pain and lameness in the horse. Equine Vet J 1995;27:296-300.
10. US Pharmacopeia. KETOPROFEN veterinary - systemic. Developed June 2, 2004. Available at: www.usp.org/pdf/EN/veterinary/ketoprofen.pdf. Accessed Aug 15, 2007.
11. Health Canada. Administrative maximum residue limits (AMRLS) and maximum residue limits (MRLS) set by Canada. Updated October 30, 2006. Available at: www.hc-sc.gc.ca/dhp-mps/vet/mrl-lmr/ mrl-lmr_versus_new-nouveau_e.html.Accessed Aug 15, 2007.
12. The European Agency for the Evaluation of Medicinal Products. EMEA/MRL/ 076/96-FINAL, March 1996, Committee for Veterinary Medicinal Products, ketoprofen (extension to pigs). Summary report. Available at: www.emea.eu.int/pdfs/vet/mrls/007696en.pdf. Accessed Aug 15, 2007.
13. Swinkels JM, Pijpers A, Vernooy JC, et al. Effects of ketoprofen and flunixin in pigs experimentally infected with Actinobacillus pleuropneumoniae. J Vet Pharmacol Ther 1994;17:299-303.
14. Hayball PJ, Nation RL, Bochner F. Enantioselective pharmaco-dynamics of the nonsteroidal antiinflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity. Chirality 1992;4:484-487.
15. Suesa N, Fernandez MF, Gutierrez M, et al. Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen. Chirality 1993;5:589-595.
16. Landoni MF, Comas W, Mucci N, et al. Enantiospecific pharmacokinetics and pharmacodynamics of ketoprofen in sheep. J Vet Pharmacol Ther 1999;22:349-359.
17. Arifah KA, Landoni MF, Frean SP, et al. Pharmacodynamics and pharmacokinetics of ketoprofen enantiomers in sheep. Am J Vet Res 2001;62:77-86.
18. Jaussaud P, Bellon C, Besse S, et al. Enantioselective pharmacokinetics of ketoprofen in horses. J Vet Pharmacol Ther 1993;16:373-376.
19. Landoni MF, Lees P. Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. Chirality 1995;7:586-597.
20. Yasui H, Yamaoka K, Nakagawa T. Moment analysis of stereo selective enterohepatic circulation and unidirectional chiral inversion of ketoprofen enantiomers in the rat. J Pharmacol Sci 1996; 85:580-585.
21. Lees P, Taylor PM, Landoni FM, et al. Ketoprofen in the cat; pharmacodynamics and chiral pharmacokinetics. Vet J 2003; 165:21-35.
22. Landoni MF, Lees P. Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in the horse. J Vet Pharmacol Ther 1996;19:466-474.
23. Arifah AK, Landoni MF, Lees P. Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat. J Vet Pharmacol Ther 2003;26:139-150.
24. Landoni MF, Lees P. Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. J Vet Pharmacol Ther 1995;18:315-324.
25. Schmitt M, Guentert TW. Biopharmaceutical evaluation of ketoprofen following intravenous, oral and rectal administration in dogs. J Pharmacol Sci 1990;79:614-616.
26. Larsen C, Jensen BH, Olesen HP. Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. Acta Pharm Nord 1991;3:71-76.
27. Owen SG, Roberts MS, Friesen WT. Rapid high-performance liquid chromatographic assay for the simultaneous analysis of non-steroidal anti-inflammatory drugs in plasma. J Chromatogr 1987;416:293-302.
28. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000;17:1551-1557.
29. The European Agency for the Evaluation of Medicinal Products. Committee for Veterinary Medicinal Products. Guidelines for the conduct of bioequivalence studies for veterinary medicinal products, 2001. Available at: www.emea.eu.int/pdfs/vet/ewp/001600en.pdf. Accessed Aug 15, 2007
30. Larsen F, Jensen BH, Olesen HP, et al. Multiple oral administration of a ketoprofen-dextran ester prodrug in pigs: assessment of gastrointestinal unavailability by deconvolution. Pharm Res 1992;9:915-919.
31. Caille G, du Souich P, Besner JG, et al. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med 1989;86:38-44.
32. McEwen J, De Luca M, Casini A, et al. The effect of food and an antacid on the bioavailability of dexketoprofen trometamol. J Clin Pharmacol Suppl 1998;38:41S-45S.
33. Nievel JG, Havard CW, Mitchell P, et al. Effect of meal size and composition on the bioavailability of ketoprofen (Oruvail). Xenobiotica 1987;17:487-492.
34. Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 1990;19:197-217.
35. Landoni MF, Cunningham FM, Lees P. Pharmacokinetics and pharmacodynamics of ketoprofen in calves applying PK/PD modelling. J Vet Pharmacol Ther 1995;18:446-450.
36. Landoni MF, Cunningham FM, Lees P. Determination of pharmacokinetics and pharmacodynamics of flunixin in calves by use of pharmacokinetic/ pharmacodynamic modeling. Am J Vet Res 1995;56:786-794.